Clinical Trial: Low-dose IL-2 ( Interleukin-2) Treatment in Macrophage Activation Syndrome（MAS）
Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional
Official Title: Safety and Efficiency Study of Low-dose IL-2 Treatment in Macrophage Activation Syndrome
Brief Summary: The investigators evaluate the effectiveness and safeness of low-dose Recombinant Human Interleukin-2 （rhIL-2） for MAS.
Detailed Summary:
Autoimmune-associated macrophage activation syndrome (MAS), also known as secondary hemophagocytic lymphohistiocytosis (HLH), is a rapidly progressing life-threatening disease. VP16 (Etoposide) is a well-known standard therapy, but is associated with substantial adverse effects, especially myelosuppression and infections , while steroids and ciclosporin (CSA) are not always efficient in this disease.
The investigators hypothesized that low- dose IL-2 could be a novel therapy in MAS. This clinical study will test the efficacy and safety of low dose IL-2 treatment in MAS. The investigators perform a single-centre pilot trial with rhIL-2 in MAS. The investigators evaluate the effectiveness and safeness of low-dose IL-2 for MAS.
Sponsor: Peking University People's Hospital
Current Primary Outcome: Disease activity on the HScore (a Score for the Diagnosis of Reactive Hemophagocytic Syndrome) [ Time Frame: 1month ]
Original Primary Outcome: Same as current
Current Secondary Outcome:
Original Secondary Outcome:
Information By: Peking University People's Hospital
Dates:
Date Received: October 2, 2015
Date Started: June 2014
Date Completion: June 2018
Last Updated: October 4, 2015
Last Verified: October 2015
